Hrituraj Singh
About Hrituraj Singh
Hrituraj Singh is the Co-Founder of Triomics, a company focused on oncology solutions, based in San Francisco, California, since 2021. He holds a Bachelor's Degree in Electrical Engineering from the Indian Institute of Technology, Roorkee, and has previous experience as a Research Intern and Research Fellow at Adobe.
Work at Triomics
Hrituraj Singh serves as Co-Founder at Triomics, a position he has held since 2021. Based in San Francisco, California, he plays a key role in the company's mission to improve cancer care through innovative technology. Triomics focuses on enhancing clinical trial enrollment and quality improvement projects in oncology. The company has developed OncoLLM™, a family of oncology-focused language models designed to support these initiatives. Triomics has garnered support from notable investors, including Lightspeed, Nexus, General Catalyst, and Y Combinator.
Education and Expertise
Hrituraj Singh earned his Bachelor’s Degree in Electrical Engineering from the Indian Institute of Technology, Roorkee, where he studied from 2015 to 2019. Prior to this, he completed his Intermediate education in Science at MM Public School from 2013 to 2015. His academic background provides a strong foundation for his work in technology and research within the healthcare sector.
Professional Background
Before co-founding Triomics, Hrituraj Singh gained valuable experience in research roles. He worked as a Research Intern at Adobe in 2018 for two months in Bengaluru, Karnataka, India. He also served as a Research Assistant at AGH University of Science and Technology in 2017 for one month in Kraków Area, Poland. Following his internship, he continued at Adobe as a Research Fellow from 2019 to 2021 for two years, further developing his expertise in research and technology.
Collaborations and Partnerships
Hrituraj Singh collaborates with a diverse range of partners in the oncology field. His work involves engaging with large NCI-designated comprehensive cancer centers as well as regional community oncology practices. These collaborations aim to enhance cancer care and improve clinical trial processes through advanced technological solutions.